San Diego-based BlossomHill Therapeutics has filed for a Nasdaq IPO seeking to raise approximately $125 million through the sale of 7.81 million shares priced between $15.00 and $17.00 each. At the midpoint of the proposed range, the company would have an implied market capitalization of approximately $465 million. BlossomHill intends to trade on the Nasdaq Global Select Market under the ticker BLSM, with the offering being led by J.P. Morgan, Leerink Partners, Guggenheim Securities, LifeSci Capital, and H.C. Wainwright & Co.
BlossomHill Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies using a structure-based, chemistry-driven drug discovery platform. Rather than relying on traditional large-scale screening methods, the company engineers novel small molecules designed to overcome known resistance mechanisms that frequently limit the effectiveness of existing targeted cancer therapies. Management believes this rational drug design approach has the potential to deliver medicines with broader mutation coverage, improved selectivity, and more durable responses than earlier generations of targeted therapies.
The company's lead product candidate, BH-30643, is currently being evaluated in the global SOLARA Phase 1/2 clinical trial for patients with EGFR-mutant non-small cell lung cancer (NSCLC). Designed as a non-covalent, macrocyclic OMNI-EGFR inhibitor, BH-30643 is intended to address a broad spectrum of EGFR mutations, including the difficult-to-treat C797S and T790M resistance mutations while maintaining selectivity over wild-type EGFR. BlossomHill plans to meet with the U.S. Food and Drug Administration during the fourth quarter of 2026 to discuss a potential accelerated approval pathway and expects to initiate a pivotal Phase 2 trial during the first quarter of 2027.
The company's second clinical-stage program, BH-30236, is a CDC-like kinase (CLK) inhibitor being developed for patients with relapsed or refractory acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). The ongoing Phase 1 study is evaluating the therapy both as a standalone treatment and in combination with venetoclax, the current standard-of-care backbone for many AML patients. Updated safety and efficacy data are expected during the first half of 2027, providing another important development milestone.
Rounding out the pipeline is BH-501284, a preclinical pan-KRAS inhibitor designed to selectively target multiple KRAS mutations while sparing HRAS and NRAS. The company believes its proprietary chemical scaffold provides prolonged target engagement and the potential for broader activity than currently available mutation-specific KRAS inhibitors. BlossomHill expects to submit an Investigational New Drug (IND) application for BH-501284 during the first quarter of 2027.
One of BlossomHill's strongest competitive advantages may be its leadership team. Founder and Chief Executive Officer Dr. J. Jean Cui is the lead inventor behind three FDA-approved targeted oncology therapies—Xalkori (crizotinib), Lorbrena (lorlatinib), and Augtyro (repotrectinib)—and previously co-founded Turning Point Therapeutics, which was acquired by Bristol Myers Squibb in 2022. Chief Medical Officer Dr. Geoffrey Oxnard is internationally recognized for his work in EGFR-mutant lung cancer and co-authored the first published description of the C797S resistance mutation, the very mutation BH-30643 is designed to overcome. Collectively, the management team has contributed to the discovery or development of more than a dozen oncology drug programs and multiple FDA-approved therapies.
Financially, BlossomHill remains a pre-revenue biotechnology company focused entirely on research and development. Operating expenses increased from $36.4 million in 2024 to $64.0 million in 2025 as clinical development accelerated, resulting in net losses of $30.7 million and $60.6 million, respectively. As of March 31, 2026, the company held $116.0 million in cash and cash equivalents, and management intends to use the proceeds from the IPO to continue advancing its three lead oncology programs while supporting additional research and general corporate operations.
BlossomHill enters the public markets with a differentiated precision oncology platform centered on rational, chemistry-based drug design and supported by one of the more accomplished leadership teams among recent biotechnology IPO candidates. While the company remains in the clinical stage and therefore faces the significant regulatory and development risks common to pre-revenue biotechnology companies, its multiple clinical assets, experienced management team, and focus on well-characterized mechanisms of drug resistance provide investors with several meaningful catalysts over the next 12 to 24 months. The investment thesis will ultimately depend on whether BH-30643 can continue producing encouraging clinical data while advancing toward a potential accelerated approval pathway, and whether BlossomHill's broader pipeline can validate its structure-based drug discovery platform across multiple oncology indications.
